Nearly 20.8 million people across the U.S. are affected with diabetes and 90% of these have type 2 diabetes, which can be termed as insulin deficiency syndrome, wherein type 2 diabetes your body does not use insulin properly. This is called insulin resistance. Patients in early stages manage their diet and control the glucose level in blood. However, progression of the disease caused due to uncontrolled levels of blood glucose results into hyperglycemia. The parenteral route of administration is the conventional method of insulin delivery. The blood glucose levels and the Insulin delivery is expected to be regularized by the Next Generation Diabetes therapy and drug delivery. Insulin can be delivered through different routes of administration such as oral and inhalation, which prevent prick pain and skin irritation due to continuous usage of conventional method.
Benefits of next generation devices over injections is the key factor driving the global next generation diabetes therapy and drug delivery market. The benefits include painless administration, non-infectious, easy portability, and no adverse effects. This might increase in market value of the products. But the problems lies when the middle income population comes in, as the product should be affordable. A majority of people prefer conventional products such as injections, as these are affordable, easily available, user-friendly. Lack of awareness among the people, less variability in products, and high cost of products in the developing countries are projected to hamper the growth of the market.
According to the Review of Diabetic Studies journal of the Society for Biomedical Diabetes Research, the 13 drug classes recommended for drug therapy of type 2 diabetes are α-glucosidase inhibitors, Biguanides, Sulfonylureas, Meglitinides (glinides), Thiazolidinediones (glitazones), Dipeptidyl peptidase 4 (DPP4) inhibitors (gliptins), Incretin mimetics, sodium/glucose cotransporter 2 (SGLT2) inhibitors (gliflozins), Amylin mimetics, bile acid sequestrants, dopamine agonists, human insulin, and insulin analogues.
Gemtuzimab ozogamicin was the first FDA approved antibody-drug conjugate and it was withdrawn from the market in 2010, 10 years after its initial approval. The market withdrawal was spurred by a clinical trial that indicated that Gemtuzimab ozogamicin not only increased mortality, but also added no benefit over alternative therapies.
The global next generation diabetes therapy and drug delivery market can be segmented based on product type, end-user, and region. In terms of product type, the market can be divided into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. Based on end-user, the global next generation diabetes therapy and drug delivery market can be classified into diagnostics/clinics, ICUs, and home health care.
The drug delivery systems (DDS) improve the administration and effect of the compounds including antibodies, peptides, vaccines, drugs, and enzymes. Oral pills and injections are the most common and conventional mode of administration of drugs presently. The technical obstacles in health, especially drug delivery, have been overcome through microtechnology. Researchers have found that microtechnology displays a broad panel of appealing features for the design and production of drug delivery systems.
The global next generation diabetes therapy and drug delivery market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the global market in terms of revenue in 2017. Rise in health care expenditure in developing countries such as India and China is projected to present significant opportunities in the market in Asia Pacific. The market in Asia Pacific is anticipated to expand at the highest CAGR during the forecast period due to rise in disposable income, increase in health care expenditure, and surge in adoption rate of advanced diabetes products.
Prominent players operating in the global next generation diabetes therapy and drug delivery market are Medtronic, Smiths Medical, Becton, Dickinson and Company, Boston Scientific Corporation, Argon Medical Devices, Inc., NIPRO Medical Corporation, Novo Nordisk A/S, Terumo Corporation, and B. Braun Melsungen AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.